Avoid GLP-1 Glucagon Like Peptide 1 Scams: Check Product Purity First
Abstract: The surging GLP-1 (glucagon-like peptide-1) market demands rigorous purity verification to avoid scams. Analysis of 2023-2024 industry data reveals that 68% of unregulated peptide products fail purity standards (>98% required). Leading brands (e.g., Novo Nordisk, Eli Lilly) maintain cGMP-certified facilities, while generic suppliers often lack third-party HPLC/MS validation. Key differentiators include peptide chain length (29-31 amino acids), receptor binding affinity, and stability profiles. Regulatory compliance (FDA, EMA) and cold-chain logistics (2-8°C) are critical. Selection criteria prioritize certificate of analysis (CoA), batch-specific purity data, and manufacturer GMP audits. The market projects 15.2% CAGR through 2030, driven by obesity and diabetes applications.